These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21447724)

  • 41. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET.
    Dimitrakopoulou-Strauss A; Georgoulias V; Eisenhut M; Herth F; Koukouraki S; Mäcke HR; Haberkorn U; Strauss LG
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):823-30. PubMed ID: 16570185
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE.
    Dobson R; Vinjamuri S; Hsuan J; Banks M; Terlizzo M; Wieshmann H; Daousi C; Poston GP; Cuthbertson DJ
    J Clin Oncol; 2013 Jun; 31(17):e272-5. PubMed ID: 23630208
    [No Abstract]   [Full Text] [Related]  

  • 43. Towards tailored radiopeptide therapy.
    Radojewski P; Dumont R; Marincek N; Brunner P; Mäcke HR; Müller-Brand J; Briel M; Walter MA
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1231-7. PubMed ID: 25792454
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
    Popp M; Strumpf A; Zöphel K; Stroszczynski C; Kotzerke J
    Nuklearmedizin; 2010; 49(1):N2-3. PubMed ID: 20336828
    [No Abstract]   [Full Text] [Related]  

  • 45. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of elevated hormone levels on physiologic accumulation of
    Watanabe M; Nakamoto Y; Koyasu S; Ishimori T; Yasoda A; Togashi K
    Ann Nucl Med; 2018 Apr; 32(3):191-196. PubMed ID: 29349562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors.
    Sänger PW; Freesmeyer M
    Clin Nucl Med; 2016 Jun; 41(6):447-53. PubMed ID: 26859210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography.
    Koch W; Auernhammer CJ; Geisler J; Spitzweg C; Cyran CC; Ilhan H; Bartenstein P; Haug AR
    Mol Imaging; 2014; 13():1-10. PubMed ID: 24824963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
    Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
    Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
    Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
    Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Luboldt W; Hartmann H; Wiedemann B; Zöphel K; Luboldt HJ
    Mol Imaging; 2010 Dec; 9(6):351-8. PubMed ID: 21084031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
    Giesel FL; Stefanova M; Schwartz LH; Afshar-Oromieh A; Eisenhut M; Haberkorn U; Kratochwil C
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
    Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
    Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
    J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.